Polarization assay. His-RXRα-LBD (1 µM), labeled co-activator peptide (D22, TIF2, Pro22) (0.1 µM), and the ligand at the indicated concentration in the assay buffer: 10 mM HEPES, pH 7.5, 150 mM NaCl, 5 mM DTT, 0.1% v/v bovine serum albumin were incubated for 60 minutes at 4 Before crystallization the protein was mixed with a 1.5-fold molar excess of compound 1 and a 3-fold excess of TIF2 NR2 cofactor peptide (686-KHKILHRLLQDSS-698). The complex was incubated for 1h at 4 °C. Initial screening was performed using JCSG+ (Qiagen), NR LBD screen (molecular dimensionsTM) and PACT (Quigen®) at 4 °C using sitting drop vapor diffusion. 200 nL reservoir solution was automatically mixed with 200 nL protein solution using a pipetting robot (Mosquito® Crystal) in a 96-well plate. The drops were equilibrated against 75 µL of reservoir solution. After two days crystals had appeared in 6 conditions. Reproduction of the crystals were performed in 15-well plates using the hanging drop vapor diffusion method. Drops with a size of 2 -3 µL using different reservoir to protein ratio were manually mixed and equilibrated against reservoirs with a volume of 500 μL. Optimal crystals were grown in two days in 3 µL drops with protein solution to reservoir ratio of 1:2 with: 1 M MIB buffer (Malonic acid, Imidazole, Boric acid), pH 8 25% (w/v) PEG 1500. The crystals were cryo-cooled in liquid nitrogen using sucrose as cryo-protectant for Xray data collections.
X-ray diffraction data was then collected using an in-house Rigaku Micromax-003 sealed tube X-ray source and a Dectris Pilatus 200K detector at 100K. The data was indexed and integrated using iMosflm and scaled and merged using Aimless. 2 Phasing was done by molecular replacement using Phaser 3 and 4OC7 as a starting model, followed by iterative rounds of refinement and manual model building using Phenix.Refine 4 and COOT 5 respectively. Model validation was performed using MolProbity prior to PDB submission (PDB code: 5LYQ). Both the S-and R-enantiomer of 1 were modeled into the observed ligand density, and by visual inspection the R-enantiomer shows a much better fit into the electron density. This is supported by an electron density fit analysis, which yields a correlation coefficient of 0.63 for the Renantiomer compared to 0.43 for the S-enantiomer (+1 means perfect fit, -1 means perfect mismatch). Additionally, a geometry analysis yields a z-score of 1.12 for the R-enantiomer and 2.84 for the S-enantiomer. The geometry z-score is the number of standard deviations that the current conformation of the molecule deviates from the bond angle/length and plane restraints that have been defined for the ligand. These restraints are generated from the MOGUL 7 crystallographic database.
Modeling and docking. The X-ray crystal structure of the complex of RXR (PDB code: 1MVC) with full agonist BMS649 was used for our modeling studies summarized in figure 1b. The energy of the system was minimized using the MAB force field as implemented in the computer program MOLOC. 8 
All types of interactions (H-bonding, lipophilic and repulsive interactions)
between spiroketal products -both R-1 and S-1 -and protein were analyzed in MOLOC.
Designed compounds were subsequently docked into the active site of RXR by using the FlexX docking module in the LeadIT suite. 9 During the docking, the binding site in the protein was restricted to 6.5 Å around the co-crystallized ligand BMS649, and the 30 top scored FlexX solutions were retained, subsequently post-scored with SEESAR. 10 The best scored pose for R-1 is shown in Figure 1 of the main manuscript. A similar strategy was used for the modeling studies summarized below in figure S3 , except this time starting from our co-crystal structure was dissolved in CH2Cl2 (11.5 mL). The solution was cooled to 0 °C and i Pr2NEt (1.9 mL, 10.63 mmol) was added. Finally chloromethyl methyl ether (0.63 mL, 8.3 mmol) was added and the mixture was stirred at 0 °C for 30 min. The reaction was then allowed to warm to room temperature and was stirred until all the starting material was consumed. After 4 hours the reaction mixture was separated between CH2Cl2 and H2O. The aqueous layer was extracted twice with CH2Cl2. The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated. The product was purified via column chromatography eluting with CH2Cl2 to yield methyl 3-allyl-4-(methoxymethoxy)benzoate as colorless oil in 80% yield over two steps. (221.44 mg, 0.67 mmol) was disolved in dry toluene (17.6 mL). NaOH (137 mg, 3.43 mmol) was added and the reaction was refluxed at 120 °C for 3.5 hour. The reaction mixture was allowed to cool to room temperature and was quenched with sat. aq. NH4Cl, the mixture was diluted with H2O and extracted twice with Et2O. The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated. The product was purified via column chromatography eluting with 17% v/v The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated. Spiroketal (±)-1. Spiroketal 7 (9 mg, 21.4 μmol) was dissolved in 1,4-dioxane/MeOH (14:5 v/v, 0.5 mL). NaOH (4 M, 50 μL) was added and the reaction was stirred at 40 °C. After 4 h the solvent was evaporated and the residue was redissoved in H2O. The aqueous solution was acidified to pH 4 and extracted three times with CH2Cl2, the combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated to obtain compound 1 in quantitative yield. 
